Abstracts tagged "dermatomyositis"

Abstract Number: 1163 • ACR Convergence 2023
Anti-melanoma Differentiation Associated Gene 5 (Anti-MDA5) Antibody Dermatomyositis: Clinical Features and Outcome in a Racially Diverse Patient Cohort
Sai Koyoda¹, Dawn Wahezi², Xianhong Xie³, Anand Kumthekar⁴, Clement Tagoe³ and Bibi Ayesha⁵, ¹Essen Medical Center, Rahway, NJ, ²Children's Hospital at Montefiore, New Rochelle, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁵Montefiore Medical Center, Bronx, NY
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody dermatomyositis typically expresses rapidly progressing interstitial lung disease (RP-ILD) and ulcerative skin lesions, with or without muscle involvement.…
Abstract Number: 1709 • ACR Convergence 2023
Tape Stripping Expression Signatures Identify Biologically Unique Juvenile Dermatomyositis Patient Subgroup Characterized by Increased Mitochondrial Dysfunction
Jessica Turnier, Celine Berthier, Sarah Vandenbergen, Christine Goudsmit, Madison McClune, Johann E. Gudjonsson, Lam Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) can signal disease onset or flare and prevent complete disease remission. The study of cutaneous expression signatures holds…
Abstract Number: 0126 • ACR Convergence 2023
Epidemiology and Retrospective Case-Control Analysis of IIM in the US Veteran Population
Vladimir Liarski, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic Inflammatory Myopathy (IIM) - comprising polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM) - is rare and difficult to study. We sought…
Abstract Number: 1164 • ACR Convergence 2023
Can We Differentiate Patients with Dysferlinopathies and Inflammatory Myopathies by Muscle Ultrasound? A Discriminant Analysis Study
Carina Soto-Fajardo¹, Sinthia Solorzano Flores¹, Abish Angeles-Acuña¹, Fabian Carranza Enriquez¹, Rosa-Elena Escobar-Cedillo², Saul Renan-Leon², Karina Arias Callejas³, Alejandra Enriquez-Luna², Graciliano Ramon-Diaz² and Carlos Pineda², ¹Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, ²Instituto Nacional de Rehabilitacion, Mexico City, Mexico, ³Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico
Background/Purpose: Immune-mediated myopathies (IMM) are a heterogeneous group of diseases characterized by inflammation and muscle weakness; among their differential diagnoses are the dysferlinopathies, which are…
Abstract Number: 1814 • ACR Convergence 2023
Silica and Other Exposures from Jobs and Hobbies Are Associated with Myositis Phenotype in a National Myositis Registry
Christine Parks¹, Jesse Wilkerson², Payam Noroozi Farhad³, Nastaran Bayat⁴, Adam Schiffenbauer⁵, Hermine Brunner⁶, Robert Goldberg⁷, Frederick Miller⁸ and Lisa Rider⁵, ¹Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, ²NIEHS/NIH, Durham, NC, ³Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁴Social Scientific Systems, DLH Holdings Corp, Silver Spring, MD, ⁵NIEHS, NIH, Bethesda, MD, ⁶Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁷Myositis Foundation, Alexandria, VA, ⁸NIH, NIEHS, Chapel Hill, NC
Background/Purpose: Growing evidence suggests that environmental factors may contribute to disease phenotype among patients diagnosed with the idiopathic inflammatory myopathies (IIM), dermatomyositis (DM), polymyositis (PM),…
Abstract Number: 008 • 2023 Pediatric Rheumatology Symposium
Treatment Response and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis
Belina Yi¹, Dawn Wahezi², Lauren Covert³, Kaveh Ardalan⁴, Joyce Hui-Yuen⁵, Natalia Vasquez Canizares², Doaa Mosad Mosa⁶, Madison Jones⁷, Colleen Correll⁸, Alexis Begezda⁹, Susan Shenoi¹⁰, Eveline Wu¹¹, Leonard Kovalick¹², William Lapin¹³, Stacey Tarvin¹⁴, Melissa Oliver¹⁵, Martha Rodriguez¹⁴, Itay Marmor¹⁶, Kevin Baszis¹⁷, Alysha Taxter¹⁸, Andrew Hanson¹⁹, Cynthia Crowson¹⁹ and Amir Orandi¹⁹, ¹Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital at Montefiore, New York, NY, ³Duke University, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁶Mansoura University Hospitals, Mansoura University Faculty of Medicine, El Mansoura, Egypt, ⁷Keck School of Medicine at University of Southern California, Los Angeles, CCA, ⁸University of Minnesota, Minneapolis, MN, ⁹Penn State, State College, PA, ¹⁰Seattle Children's Hospital, Seattle, WA, ¹¹UNC Chapel Hill, Chapel Hill, NC, ¹²UNC Health Care, Durham, NC, ¹³Connecticut Children's, Hartford, CT, ¹⁴Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ¹⁵Indiana University, Indianapolis, IN, ¹⁶Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ¹⁷Washington University School of Medicine, St Louis, MO, ¹⁸Nationwide Children's Hospital, Columbus, OH, ¹⁹Mayo Clinic, Rochester, MN
Background/Purpose: Calcinosis is a poorly understood and morbid complication of juvenile dermatomyositis (JDM). As there is no consensus treatment approach for calcinosis, and limited knowledge…
Abstract Number: 018 • 2023 Pediatric Rheumatology Symposium
Using the Electronic Health Record to Identify Subjects with Rheumatic Disease
Alysha Taxter¹, Matthew Basiaga², Rajdeep Pooni³, Caitlan Pinotti⁴, Lisa Buckley⁵ and CARRA Registry Investigators⁶, ¹Nationwide Children's Hospital, Columbus, OH, ²Mayo Clinic, Rochester, MN, ³Stanford University, Palo Alto, CA, ⁴Duke, Durham, NC, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶CARRA, Washington, DC
Background/Purpose: Research teams spend hours manually searching the electronic health records (EHRs) to identify potential candidates eligible for recruitment to the Childhood Arthritis and Rheumatology…
Abstract Number: 023 • 2023 Pediatric Rheumatology Symposium
Effect of Type 1 Interferons and JAK Inhibitors on Gene Expression in Bioengineered Pediatric Skeletal Muscle
Lauren Covert¹, Joseph Prinz², Hailee Patel³, Jeffrey Dvergsten⁴ and George Truskey³, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Department of Biostatistics and Bioinformatics, Durham, NC, ³Duke University, Department of Biomedical Engineering, Durham, NC, ⁴Duke University Hospital, Durham, NC
Background/Purpose: Genetic studies of new-onset juvenile dermatomyositis (JDM) exhibit elevation of Type 1 interferons (IFN 1) IFNα and IFNβ in blood, skin, and muscle. To…
Abstract Number: 027 • 2023 Pediatric Rheumatology Symposium
Identifying and Understanding JDM in Africa: A Survey of Rheumatology Care Providers from Africa
Jessica Perfetto¹, Laura Lewandowski², Dawn Wahezi¹, Christiaan Scott³ and Angela Migowa⁴, ¹Children's Hospital at Montefiore, New York, NY, ²NIAMS, NIH, Bethesda, MD, ³Red Cross War Memorial Children's Hospital, ⁴Aga Khan University, Nairobi, Kenya
Background/Purpose: There is a paucity of data on pediatric rheumatic disease (PRD) in low and middle-income countries (LMIC), creating a false perception of low prevalence…
Abstract Number: 028 • 2023 Pediatric Rheumatology Symposium
Achieving Medication-Free Remission in Juvenile Dermatomyositis
Harneet Ghumman¹, Ilaria Maccora², Hermine Brunner¹, Amy Cassedy³, Mekibib Altaye², Asra Firdous¹, Alexei Grom¹, Daniel Lovell¹, Angela Merritt¹, Megan Quinlan-Waters¹ and Sheila Angeles-Han², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis. Systemic immunosuppression is needed. Evidence is limited…
Abstract Number: 064 • 2023 Pediatric Rheumatology Symposium
Towards the Development of Composite Parent-Centered Disease Activity Scores for Juvenile Dermatomyositis
Silvia Rosina¹, Ana Isabel Rebollo-Giménez², Letizia Tarantola³, Roberta Naddei⁴, Alessandro Consolaro², Angela Pistorio⁵ and Angelo Ravelli⁶, ¹IRCCS Istituto Giannina Gaslini, Genova, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Infiammatorie, Genova, Italy, ³Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genova, Italy, ⁴Università degli Studi di Napoli Federico II, Dipartimento di Scienze Mediche Traslazionali, Napoli, Italy, ⁵IRCCS Istituto Giannina Gaslini, Direzione Scientifica, Genova, Italy, ⁶IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy
Background/Purpose: Increasing attention has been recently paid to the development of parent- and child-centered composite DAS for the assessment of health status of children with…
Abstract Number: 066 • 2023 Pediatric Rheumatology Symposium
Telemedicine Use in the Assessment of Juvenile Myositis: A Mixed-Methods Study of an International Healthcare Provider Experience
Y. Ingrid Goh¹, Peter Blier², Bianca Lang³, Marietta De Guzman⁴, Julie Fuller⁵, Kristin Houghton⁶, Kathryn Cook⁷, Susan Kim⁸, Vanessa Carbone¹, Heather Tory⁹, Jo-Anne Marcuz¹, Albert Chow¹⁰, Liza McCann¹¹, Charalampia Papadopoulou¹², Clarissa Pilkington¹³ and Stacey Tarvin¹⁴, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Retired, Amherst, MA, ³Dalhousie University - Halifax, Halifax, NS, Canada, ⁴Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁵UT Southwestern, Dallas, TX, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷Akron Children's Hospital, Akron, OH, ⁸UCSF Benioff Children's Hospital, San Francisco, CA, ⁹Connecticut Children's Medical Center, S Glastonbury, CT, ¹⁰Loma Linda University, Loma Linda, CA, ¹¹Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ¹²UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, ¹³Great Ormond Street Hospital, London, United Kingdom, ¹⁴Riley Hospital for Children at Indiana University Health, Indianapolis, IN
Background/Purpose: Care of patients with juvenile myositis (JM) involves complex assessments performed by specialized healthcare providers (HCPs). Restrictions during the COVID-19 pandemic required the rapid…
Abstract Number: 070 • 2023 Pediatric Rheumatology Symposium
The Impact of the COVID-19 Pandemic on Patients with Juvenile Idiopathic Inflammatory Myopathies
Dawn Wahezi¹, Dominique Jerome¹, Evin Rothschild¹, Jeffrey Dvergsten², Stacey Tarvin³, Susan Kim⁴ and Tamar Rubinstein¹, ¹Children's Hospital at Montefiore, New York, NY, ²Duke University Hospital, Durham, NC, ³Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ⁴UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Since the onset of the COVID-19 pandemic, there have been concerns regarding the risks of SARS-CoV-2 infection in patients with juvenile idiopathic inflammatory myopathies…
Abstract Number: 086 • 2023 Pediatric Rheumatology Symposium
Systemic Sclerosis Overlap Syndrome: A Case Series from a Single Large Pediatric Center
Jessica Nguyen¹, Miriah Gillispie-Taylor¹, Eyal Muscal¹ and Marietta Deguzman², ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Childhood-onset systemic sclerosis (SSc) is a rare but potentially life-threatening autoimmune condition with features including immune, fibrotic, and vascular manifestations affecting the skin and…
Abstract Number: 099 • 2023 Pediatric Rheumatology Symposium
The Impact of the COVID-19 Pandemic on Juvenile Dermatomyositis
Tresa Ambooken¹, Sangati Kadakia¹, Tara Lozy¹, Brianna Bulbin², Suhas Ganguli³, Dawn Wahezi⁴ and Sivia Lapidus¹, ¹Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Hackensack Meridian School of Medicine, Hackensack, NJ, ³Department of Pediatrics, K. Hovnanian Children's Hospital, Jersey Shore University Medical Center, Neptune City, NJ, ⁴Children's Hospital at Montefiore, New York, NY
Background/Purpose: Juvenile Dermatomyositis (JDM) is theorized to occur in a genetically susceptible individual as a response to an environmental trigger, leading to autoimmunity and inflammation.…

« Previous Page
1
…
6
7
8
9
10
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].